Expanding screening for rare metabolic disease in the newborn: An analysis of costs, effect and ethical consequences for decision-making in Finland

Acta Paediatrica, International Journal of Paediatrics

Volumn 94, Issue 8, 2005, Pages 1126-1136

  Autti Rämö, Ilona ^a   Mäkelä, Marjukka ^a   Sintonen, Harri ^a,b   Koskinen, Hanna ^a   Laajalahti, Liisa ^a   Halila, Ritva ^c   Kääriäinen, Helena ^d   Lapatto, Risto ^b   Näntö Salonen, Kirsti ^e   Pulkki, Kari ^f   Renlund, Martin ^b   Salo, Matti ^g   Tyni, Tiina ^b  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c National Advisory Board on Research Ethics   (Finland)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Metabolic disorder; Newborn; Screening

Indexed keywords

GLUTARIC ACID; LONG CHAIN ACYL COENZYME A DEHYDROGENASE; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE;

ACIDURIA; ARTICLE; CONGENITAL ADRENAL HYPERPLASIA; CONGENITAL HYPOTHYROIDISM; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISABILITY; ENZYME DEFICIENCY; FINLAND; HEALTH CARE COST; HEALTH PROGRAM; HUMAN; MEDICAL DECISION MAKING; MEDICAL ETHICS; METABOLIC DISORDER; NEWBORN; NEWBORN SCREENING; PHENYLKETONURIA; PRIORITY JOURNAL; QUALITY OF LIFE; TANDEM MASS SPECTROMETRY;

EID: 23844439707     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1080/08035250510029497     Document Type: Article

References (37)

1. Bickel H, Gerrard J, Hickmans EM. The Influence of phenylalanine intake on the chemistry and behaviour of a phenylketonuric child. Acta Paediatr Scand 1954;43:64-88.
2. Guthrie R, Susi A. A simple method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 1963;32:318-43.
3. Waisbren S, Albers S, Amato S, Ampola M, Brewster T, Demmer L, et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 2003;290:2564-72.
4. Norio R. Finnish disease heritage I: characteristics, causes, background. Hum Genet 2003;112:441-56.
5. Palo J. Prevalence of phenylketonuria and some other metabolic disorders among mentally retarded patients in Finland. Acta Neurol Scand 1967;43:573-9.
6. Simell O. PKU-sjukdomen i Finland - en populationsgenetisk kuriositet. Läkartidningen 1974;71:1170.
7. Visakorpi JK, Palo J, Renkonen O-V. The incidence of PKU in Finland. Acta Paediatr Scand 1971;60:666-8.
8. Virtanen M, Perheentupa J, Mäenpää J, Pitkänen L, Pikkarainen J. Finnish national screening for hypothyroidism. Eur J Pediatr 1984;143:2-5.
9. Wilson J, Jungner G. Principles and practice of screening for disease. Geneva: WHO; 1968.
10. The Danish Council of Ethics. Screening - a report. Copenhagen: Danish Council of Ethics; 2001. p 1-188.
11. Suolinna E-M. Personal communication. 2002.
12. Apajasalo M, Sintonen H, Holmberg C, Sinkkonen J, Aalberg V, Pihko H, et al. Quality of life in early adolescence: A sixteen-dimensional heath-related measure (16D). Qual Life Res 1996;5:205-11.
13. Patja K, Iivanainen M, Oksanen H, Vesala H, Ruoppila I. Life expectancy of persons with intellectual disability: A follow-up study from 1962 to 1997. J Intellect Disabil Res 2000;45:591-9.
14. Rosche A. Personal communication. 2002.
15. Wilcken B. Personal communication. 2002.
16. Honkasalo T, Ostrup J. Personal communication. 2002.
17. Clayton PE, Miller WL, Oberfield SE, Ritzen EM, Sippell WG, Speiser PW. Consensus statement of 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Laeson Wilkins Peadiatrics Endocrine Society. Horm Res 2002;58:188-95.
18. Pang S, Wallace MA, Hofman K, Thuline HC, Dorche C, Lyon IGT, et al. Worldwide incidence in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988;81:866-74.
19. Fromenty B, Mansouri A, Bonnefont J-P, Courtois F, Munnich A, Rabier D, Pessayre D. Most cases of medium-chain acyl-CoA dehydrogenase deficiency escape detection in France. Hum Genet 1996;97:367-8.
20. Seddon H, Gray G, Pollit R, Iitiä A, Green A. Population screening for the common G985 mutation causing medium-chain acyl-CoA dehydrogenase dificiency with Eu-labeled oligonucleotides and the DELFIA system. Clin Chem 1997;43:436-42.
21. Carpenter K, Wiley V, Sim KG, Heth D, Wilcken B. Evaluation of newborn screening for medium chain acyl-CoA dehydrogenase deficiency in 275 000 babies. Arch Dis Child Fetal Neonatal Ed 2001;85:F105-9.
22. Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl J Med 2003;348:2304-12.
23. Jääskeläinen J. 21-Hydroxylase deficiency. Long-term outcome and correlation of CYP21 genotype with phenotype. Kuopio: Faculty of Medicine, Kuopio University; 2000. p 98.
24. Tyni T. Clinicopathological and ophthalmic features of long-chain 3-hydroxyl-CoA dehydrogenase deficiency. Helsinki: Department of Child Neurology, University of Helsinki; 1998. p 50.
25. Jääskeläinen J, Levo A, Voutilainen R, Partanen J. Population-wide evalution of disesase manifestation in relation to molecular genotype in steroid 21-hydroxylase (CYP21) deficiency: good correlation in a well defined population. J Clin Endocrinol Metab 1997;82:3293-7.
26. Brackett JC, Sims HF, Steiner RD, Nunge M, Zimerman EM, deMartinville B, et al. A novel mutation in medium chain acyl-CoA dehydrogenase causes sudden neonatal death. J Clin Invest 1994;94:1477-83.
27. Ziadeh R, Hoffman EP, Finegold DN, Hoop RC, Brackett JC, Strauss AW, Naylor EW. Medium Chain Acyl-CoA dehydrogenase deficiency in Pensylvania: Neonatal screening shows high incidence and unexpected mutation frequencies. Pediatr Res 1995;37:675-8.
28. Andresen BS, Dobrowolski SF, O'Reilly L, Muenzer J, McCandless SC, Frazier DM, Udvari S, et al. Medium-chain Acyl:coa dehydrogenase (MCAD) mutations identified by MS/ MS based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 2001;68:1408-18.
29. Goodman S, Frerman F. Organic acidemias due to defects in lysine oxidation: 2-ketoadipic acidemia and glutaric acidemia. In: Scriver C, Beaudet A, Valle D, Sly W, editors. The metabolic and molecular bases of inherited disease. Yhdysvallat: McGraw-Hill Companies; 2001. p 2195-204c.
30. Benfield D, Leib S, Vollman J. Grief responses of parents to neonatal death and parent participation in deciding care. Pediatrics 1978;62:171-7.
31. Rowe J, Clyman R, Green C, Mikkelsen C, Haight J, Ataide L. Follow-up of families who experienced a perinatal death. Pediatrics 1978;62:166-70.
32. Dyregrov A, Matthiesen S. Anxiety and vulnerability in parents following the death of an infant. Scand J Psychol 1987;28:16-25.
33. Mandell F, Dirks-Smith T, Smith MF. The surviving child in the SIDS family. Pediatrician 1988;15:217-21.
34. DeFrain JD, Ernst L. The psychological effects of sudden infant death syndrome on surviving family members. J Fam Pract 1978;6:985-9.
35. McNally E, Cambon-Thomsen A, Brazell C, Cassiman J-J, Kent A, Lindpaintner K, et al. The 25 recommendations on the ethical, legal and social implications of genetic testing. Luxembourg: European Commission; 2004.
36. Pollitt RJ, Green A, McGabe CJ, Booth A, Cooper NJ, Leonard JV, et al. Neonatal screening for inborn errors of metabolism: cost, yield and outcome. Health Technol Assess 1997;1:1-202.
37. Rawlins M, Culyer A. National Institute for Clinical Excellence and its value judgements. Br Med J 2004;329:224-7.